15 Costly Drugs Will Get Medicare Price Cuts in 2027: Will You Save?
The Centers for Medicare & Medicaid Services extended a safety net to older Americans by announcing significant price reductions on 15 high-cost prescription drugs, effective in 2027.
On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) announced significant price reductions for 15 high-cost prescription drugs used by millions of Medicare beneficiaries. That's a major win for older Americans.
The negotiated "maximum fair prices," made possible by the 2022 Inflation Reduction Act, promise to save the program $12 billion annually compared with last year's Medicare spending on 15 widely used drugs to treat cancer and other serious chronic conditions that hit older adults hardest.
Previously, the Biden administration reached deals to lower the costs of 10 prescription drugs, including several for heart disease and diabetes, which are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027, with seniors expected to see an estimated $685 million in out-of-pocket relief.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Historically, prescription drug costs have wreaked havoc on many seniors' budgets, with some rationing doses or skipping their meds altogether due to high costs, according to a survey by research group KFF.
For the roughly 5.3 million Medicare beneficiaries who take these 15 medications, and the new $2,100 annual out-of-pocket cap in Medicare Part D, starting in 2026, 2027 can’t come soon enough.
For decades, Medicare was prohibited by law from negotiating drug prices directly with manufacturers, resulting in older Americans paying two to four times what patients in Europe or Canada paid for the same medicines.
Seniors like 72-year-old retiree Ryan Whitworth of Florida, who relies on Xtandl for prostate cancer, could see his monthly copays halved. “Finally, I won’t have to choose between meds and groceries,” he told Kiplinger.
Below is the full list of the 15 drugs and their new Medicare maximum fair prices compared with the 2024 list prices. All figures are for a typical 30-day supply. The numbers are rounded to the nearest dollar where applicable.
Drug Name | Commonly Treated Conditions | 2024 List Price | 2027 Medicare Price | % Reduction |
Ozempic; Rybelsus; Wegovy | Type 2 diabetes; Type 2 diabetes & cardiovascular disease; Cardiovascular disease & obesity/overweight | $959 | $274 | -71% |
Trelegy Ellipta | Asthma; Chronic obstructive pulmonary disease | $654 | $175 | -73% |
Xtandi | Prostate cancer | $13,480 | $7,004 | -48% |
Pomalyst | Kaposi sarcoma; Multiple myeloma | $21,744 | $8,650 | -60% |
Ofev | Idiopathic pulmonary fibrosis | $12,622 | $6,350 | -50% |
Ibrance | Breast cancer | $15,741 | $7,871 | -50% |
Linzess | Chronic idiopathic constipation; irritable bowel syndrome with constipation | $539 | $136 | -75% |
Calquence | Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma | $14,228 | $8,600 | -40% |
Austedo; Austedo XR | Chorea in Huntington’s disease; Tardive dyskinesia | $6,623 | $4,093 | -38% |
Breo Ellipta | Asthma; Chronic obstructive pulmonary disease | $397 | $67 | -83% |
Xifaxan | Hepatic encephalopathy; Irritable bowel syndrome with diarrhea | $2,696 | $1,000 | -63% |
Vraylar | Bipolar 1 disorder; Major depressive disorder; Schizophrenia | $1,376 | $770 | -44% |
Tradjenta | Type 2 diabetes | $488 | $78 | -84% |
Janumet; Janumet XR | Type 2 diabetes | $526 | $80 | -85% |
Otezla; Otezla XR | Oral ulcers in Behçet’s Disease; Plaque psoriasis; Psoriatic arthritis | $4,722 | $1,650 | -65% |
The “2024 List Price” column shows the gross Wholesale Acquisition Cost (WAC) that Medicare Part D plans were charged in 2024 for a 30-day supply, before any rebates or discounts.
The “2027 Medicare Price” column is the Maximum Fair Price (MFP) manufacturers must offer Medicare starting January 1, 2027, for a 30-day supply.
Sources: CMS, November 2025 (pdf); Medicare prescription drug affordability fact sheet; Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability, Year 2027 (pdf)
List prices reflect typical Part D gross costs before rebates.
Related content
- 16 Strategies to Save Money on Prescription Drugs
- Here Are the 10 Medicare Negotiated Drug Prices
- Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know
- Seven Medicare Changes Coming in 2026
- Brace for Higher Health Costs in 2026: A Look at Projected Medicare Premiums
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

For the past 18+ years, Kathryn has highlighted the humanity in personal finance by shaping stories that identify the opportunities and obstacles in managing a person's finances. All the same, she’ll jump on other equally important topics if needed. Kathryn graduated with a degree in Journalism and lives in Duluth, Minnesota. She joined Kiplinger in 2023 as a contributor.
-
How Prices Have Changed in Trump's First YearTrump campaigned on bringing prices down for Americans. Here's where prices stand one year into his second term.
-
New California Wealth Tax for 2026: What's Happening NowState Taxes California has considered taxing wealth before, but the latest proposal seems to be different.
-
Your 5-Step Guide to Discovering Whether a Lawyer Is ShadyResearch shows you can't rely on some state bar websites to vet a lawyer you're considering hiring. Here's how to check out a lawyer before you hire.
-
Are You the Doer or the Visionary of Your Advisory Practice? Here's How You Can Make the Leap to Chief Vision OfficerThe key is to transition from a tactical "doer" to a strategic "chief vision officer" by building the teams, processes and brand so your practice can grow.
-
You've Heard It Before, But This Investment Advice Still Pays Off"Time in the market beats timing the market" ¬— been there, done that, right? But don't write off the underlying advice. There's a reason it's a popular saying.
-
6 Champagne Problems Successful Retirees FaceWhat do you do if your biggest financial threat is simply having too much of a good thing — money?
-
A Portfolio Checklist If You're Planning to Retire in 2027Are you planning to retire in 2027? This portfolio checklist will help put you on the right path.
-
How to Avoid Being Buried by the Tax Avalanche in Retirement: Tips From a Wealth AdviserAll that cash you have in tax-deferred accounts could launch you into a higher tax bracket when you start withdrawals. It's time to protect your income.
-
I'm a Financial Adviser: This Is the Real Secret to Retirement SuccessFor real retirement security, forget about chasing returns and focus instead on the things you can control: income, taxes, risk-taking and decision-making.
-
Is Your Retirement Plan Based on Social Security Fact or Fiction?One in two Americans don't know much about Social Security — and some are basing their retirement on mistaken beliefs. It's time to separate fact from fiction.
-
Are You Investing to Score Points or Make Money? Cautionary Tales From an Investment AdviserHave you become numb to risk? Is your brokerage app or website fueling your desire to trade? An investment adviser explains why it always pays to be cautious.